Revelation Biosciences, INC 10-Q quarterly reports

Revelation Biosciences reported increased operating expenses and net losses for the six months ended June 30, 2026, raising substantial doubt about its ability to continue as a going concern and facing potential Nasdaq delisting.

Revelation Biosciences reports a reduced net loss and increased cash, but raises substantial doubt about its ability to continue as a going concern without further capital raises.

Revelation Biosciences reports a net loss of $4.5M for Q2 2025, highlighting ongoing challenges in funding and development.

Revelation Biosciences reports a net loss of $2.1 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern due to insufficient cash reserves.

Revelation Biosciences reported a net loss of $2.2 million for Q3 2024 and is addressing Nasdaq listing compliance issues.

Revelation Biosciences has filed an amendment to its original quarterly report to include previously omitted language in its certifications.

Revelation Biosciences has filed an amended 10-Q report to correct an omission in the certifications of its principal executive and financial officers.

Revelation Biosciences reported a net loss of $11.1 million for the first half of 2024 and faces substantial doubt about its ability to continue as a going concern due to recurring losses and the need for additional capital.

Revelation Biosciences reported a net loss of $2.7 million for the first quarter of 2024 and expressed substantial doubt about its ability to continue as a going concern without additional funding.